Context: Localization of the primary tumor and detection of metastases are essential for preoperative planning and postoperative management of pheochromocytoma. When computed tomography (CT) and magnetic resonance imaging are inadequate, functional imaging adds important information in this respect.
P
heochromocytoma and paraganglioma are rare tumors but should be considered as a differential diagnosis in patients with hypertension and sympathetic nerve hyperactivity such as palpitations, sweating, gastrointestinal symptoms, and headache. These symptoms may occur due to hormonal secretion from neuroendocrine tumors arising from the catecholamine-producing chromaffin cells in the adrenal medulla, and less frequently in extraadrenal sympathetic and parasympathetic paraganglia (1, 2) . Diagnosis is generally performed by means of radiological imaging by computed tomography (CT) or magnetic resonance imaging (MRI) with plasma and urinary biochemical evaluation (2) (3) (4) . In many centers, additional functional imaging is performed routinely, re-gardless of CT/MRI findings. The incidental finding of an adrenal tumor by radiological imaging that has been performed because of nonadrenal symptoms, a so-called incidentaloma, is increasingly common. They are found in approximately 5% of abdominal CT examinations (5, 6) . Radiological discrimination between the most frequent type of incidentaloma, the benign adrenocortical adenoma, and a pheochromocytoma may sometimes be difficult, even though dedicated evaluation algorithms are used (7, 8) . Moreover, tumor staging of malignant pheochromocytoma/paraganglioma may require functional imaging.
Patients with hereditary syndromes such as multiple endocrine neoplasia type II (MEN II, mutations in the RET gene), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (NF1), or mutations in the succinyl dehydrogenase subunits B (SDHB), C, and D or in recently discovered susceptibility genes such as SDHA, MAX, TMEM127, SDHAF2, EGLN1/PHD2, and KIF1B␤ are all at risk of developing pheochromocytoma or paraganglioma (9 -11) . While under surveillance in known mutation carriers, minute changes in catecholamine levels in serum or urine indicate a small developing tumor, which is generally difficult to detect at an early stage. These tumors are nevertheless important to find because of the risks associated with the sympathicomimetic symptoms.
The basic functional method for imaging of pheochromocytoma is methyl-iodo-benzylguanidine (MIBG) scintigraphy. However, even with three dimensional acquisitions by single-photon computed emission tomography (SPECT), the spatial resolution is low (ϳ1.5 cm) and the detection of small lesions is often difficult. The spatial resolution by positron emission tomography (PET) is better, approximately 0.5 cm, and various tracers for PET imaging have been used for imaging of these tumors. The commonly used 2-[18F] fluoro-2-deoxy-D-glucose (FDG) demonstrated a 72% patient-based sensitivity in patients with pheochromocytoma or 100% in SDHB-associated pheochromocytoma and paraganglioma (12, 13 (17, 18) . However, the reported results differ, clearly illustrating the difficulties in functional imaging in pheochromocytoma and paraganglioma. Consequently, the potential benefits of functional imaging in addition to the conventional radiological methods are substantial.
HED is a catecholamine substrate analog. Its mode of transmembrane transport is similar to the neurotransmitter norepinephrine, which is selectively and rapidly transported into sympathetic neuron by the norepinephrine transporter. In the past, HED has been evaluated for PET imaging of pheochromocytoma in smaller groups of patients (19 -21) . The additional value of HED-PET for the pre-and postoperative clinical management of pheochromocytoma has also been demonstrated in comparison to MIBG scintigraphy, FDG-PET and CT/ MRI (21) . Over the past few years, technical developments have allowed combined SPECT/CT and PET/CT imaging for more accurate tumor localization. The aim of this single-center study was to evaluate the diagnostic value of HED-PET and PET/CT in a larger cohort of patients examined over the past 11 yr, also including patients with pheochromocytoma in hereditary syndromes. PET measurements of HED tumor uptake were performed and correlated with clinical, histopathological and biochemical data.
Patients and Methods

Patients
During the study period, March 2000 to April 2011, 170 HED-PET examinations were performed on 134 patients at the PET Center (Uppsala University Hospital, Uppsala, Sweden). Of these, there were 69 stand-alone PET and 101 combined PET/CT examinations. There were 114 patients who underwent examination once, whereas 20 patients were investigated repeatedly. Clinical data of the patients, including the imaging results (CT, MRI, and 123 I-MIBG), clinical symptoms and medical outcome, blood and urine examinations, and pathological data, were obtained from the hospital's computer servers. Patient characteristics, classification of patient groups, and indication of HED-PET and PET/CT are shown in Table 1 . In the preoperative setting, a total of 103 examinations were performed in 100 patients with suspected pheochromocytoma or paraganglioma (94 examinations in 92 patients because of the presence of clinical symptoms and/or biochemical results and/or positive imaging studies, whereas nine examinations in eight patients as a part of screening for hereditary disease). Sixty-seven examinations in 34 patients were performed after surgery for pheochromocytoma (n ϭ 53), paraganglioma (n ϭ 8), adrenocortical adenoma (n ϭ 1), and various endocrine tumors (n ϭ 5) including a malignant neuroendocrine tumor originating in the left kidney hilus, a malignant neuroblastoma originating in the left adrenal gland, a malignant ganglioneuroblastoma originating in the left adrenal gland, a lung carcinoid, and a small bowel carcinoid. In this postoperative group, six examinations in six patients without symptoms, positive biochemical evidence, and positive image study were performed as a part of a scheduled postoperative follow-up for large size pheochromocytoma (n ϭ 2), malignant pheochromocytoma (n ϭ 2), paraganglioma (n ϭ 1), and malignant paraganglioma (n ϭ 1). Of the total 170 examinations, 21 examinations were performed in patients with MEN II/NF1/ VHL (11 as preoperative examination, seven as follow-up after surgery, and three as monitoring treatment of recurrent pheochromocytoma/paraganglioma), and 149 examinations were in patients without hereditary tumor syndrome (92 as preoperative examination, 32 as follow-up after surgery, and 25 as monitoring treatment of recurrent disease).
Malignant tumor was defined as the presence of lymph node or distant metastasis at nonchromaffin sites. Benign tumor was defined as tumor without any clear evidence of metastasis. Altogether 16 patients had malignant tumor in our patient group.
The study was approved by the local ethics and radiation safety committees and all patients gave informed consent. The The median was calculated assuming that the undetected values presented at half of the detection limit. PHEO/PGL, Pheochromocytoma or paraganglioma; UD, undetectable. a Positive symptom means that the patient has at least one sympathetic symptom.
experiments were performed in accordance with the World Medical Association's Declaration of Helsinki.
HED-PET and PET/CT examination procedures
11 C-Hydroxyephedrine was produced as previously described (20) . From March 2000 until December 2004, a standalone PET scanner (ECAT EXACT HR Plus; Siemens/CTI, Knoxville, TN) was used. The PET examinations were performed in a two-dimensional mode and 63 contiguous 2.5-mm slices with a 5.6-mm transaxial and a 5.4-mm axial resolution were recorded. The PET camera's axial field of view (FOV) was 155 mm and the transaxial FOV was 585 mm. The patients were placed supine on the scanner couch and a recent contrast-enhanced CT was used to position the tumor region within the PET scanner's FOV. The CT examination was also used for anatomical correlation of the PET image findings. After a short 2-min transmission scan to locate the right diaphragmatic cupola as a reference, a 10-min transmission scan was performed using Germanium-68 rotating line sources for attenuation correction of the subsequent emission scan. Approximately 10 -12 MBq/kg body weight, mean 652 (range 91-1665) MBq of 11 C-HED was injected as an intravenous bolus and a dynamic 45-min examination sequence comprising 14 time frames was started simultaneously. Reconstruction of the data into transverse PET images was performed using filtered back projection and a Gauss filter. PET data were corrected for attenuation and scatter. From March 2005 onward, a combined PET/CT scanner (GE Discovery ST; General Electric Medical Systems, Milwaukee, WI) was used. The PET scanner produced 47 slices with an axial FOV of 157 mm and a transaxial FOV of 700 mm. The spatial resolution was approximately equal to the individual crystal size in the block (6.3 ϫ 6.3 mm). Attenuation correction of the PET images used a low-dose CT examination that was performed before the PET acquisition.
Image evaluation
Qualitative PET and PET/CT image interpretation was performed at the time of examination by a nuclear medicine specialist or a radiologist, and the image findings were recorded in the radiological report. The examinations were then reviewed by a radiologist (A.S.) with 19 yr PET and PET/CT experience. Image reading of HED-PET was both at the original evaluation and at reevaluation performed with clinical information available. Qualitative image reassessment was performed on a computer workstation in the transaxial, coronal, and sagittal planes. Any focal accumulation of HED exceeding the normal physiological regional tracer uptake was regarded as pathological and was quantified. Physiological HED uptake in regions such as the salivary glands, myocardium, liver, spleen, pancreas, and normal adrenal glands (20) was disregarded.
PET measurements of tracer uptake in tumors and normal adrenal glands were performed using the standardized uptake value (SUV). SUV was calculated for each pixel by dividing its radioactivity concentration (bequerels per milliliter) by the injected radioactivity (bequerels) per gram of body weight. Regions of interest (ROI) were manually drawn in the SUV images. The average SUV (SUVaverage) was measured by drawing an isocontour to delineate 50% of the highest radioactivity concentration as a 50% cutoff ROI. The SUVaverage as well as the pixel with the highest uptake (SUVmax) was recorded. A large circular ROI was drawn in the posterior part of the right liver lobe, and the SUVaverage in liver was recorded as a normal tissue reference (SUVliver). If a primary tumor was not found, the highest SUV in the adrenal glands was recorded. For further analysis, the quotients SUVmax/SUVliver and SUVaverage/SUVliver were also calculated.
All patients were regularly monitored with routine peripheral-blood or urine tests and clinical examinations two to three times per year. Image evaluation by ultrasonography, CT/MRI, or HED-PET or PET/CT was performed when recurrent disease was suspected.
Statistical analysis
Data in the tables are given as range, median, or mean Ϯ SD. Statistical analyses were performed using the STATISTICA software (Statsoft Inc., Tulsa, OK). The t test and MannWhitney U test were used to analyze numerical data. Pearson's correlation coefficient analysis was used to test the association of two variables. P Ͻ 0.05 was considered statistically significant.
Results
HED-PET and PET/CT image interpretation
Indications for submitting the patients to HED-PET and PET/CT are given in Table 1 . In 64% preoperatively and 55% postoperatively, image findings at CT/MRI contributed to the decision to perform HED-PET. Two typical HED-PET examinations in one patient are demonstrated in Figure 1 . In the calculation of sensitivity and specificity, 164 HED-PET and PET/CT from patients with sympathicomimetic symptoms or positive biochemical tests were included. Altogether there were 60 positive and 104 negative examinations (Table 2) . Based on the clinical and imaging follow-up data as well as histopathological results after removal of these tumors, there were six false-negative examinations and no false-positive results, yielding a sensitivity of 91%, 100% specificity, 100% positive predictive value, and 94% negative predictive value.
One patient with a false-negative examination had a 2.5 ϫ 3 cm tumor in the left adrenal gland at CT, had sympathicomimetic symptoms and positive biochemical results, and no family history of pheochromocytoma. However, HED-PET demonstrated low tumor SUV (SUVmax 4.5, SUVaverage 3.1) but a high SUV in the normal adrenal gland (SUV 15). At the patient's subsequent left adrenalectomy, the histopathological diagnosis of the tumor (2.5 ϫ 2 cm) was pheochromocytoma.
The second false-negative examination was performed in a case of malignant paraganglioma, in which the tumor adjacent to the right adrenal gland (1.5 ϫ 1.5 ϫ 0.8 cm) was not visualized on HED-PET (SUVmax 8.8, SUVaverage 6.3), although MIBG scintigraphy and FDG-PET were positive.
A third patient with a false-negative HED-PET had a medical history of a nonradical resection of a large (14 ϫ 10 ϫ 8 cm) malignant nodular ganglioneuroblastoma originating in the left adrenal gland. Postoperative MRI and MIBG scintigraphy demonstrated the remaining tumor (Ͻ1 cm) located between the aorta and the inferior vena cava, but HED-PET failed to detect the lesion. The three remaining false-negative examinations were of patients with the MEN II syndrome and will be described in the next paragraph.
HED-PET and PET/CT in MEN II patients
In total, 15 HED-PET and PET/CT examinations were performed on 11 patients with MEN II (Table 2) . Nine patients underwent HED-PET once, one patient was examined twice, and one patient was examined four times. Seven examinations were performed on six patients as a screening procedure, regardless of symptoms and biochemical results. Eight postoperative follow-up examinations were performed after adrenalectomy on five patients. The patient who underwent HED-PET four times had the first HED-PET as a postoperative follow-up, whereas the following three examinations were performed to monitor the effect of radiofrequency ablation and 131I-MIBG therapy of liver metastases.
One patient (false negative examination no. 4 and 5) was without sympathicomimetic symptoms, had undergone thyroidectomy for medullary thyroid cancer, and was on medication with Everolimus due to metastatic disease. The patient had two false-negative HED-PET results despite biochemical signs of pheochromocytoma and a 1-cm lesion in the left adrenal gland at CT. In addition, two subsequent HED-PET examinations failed to depict the tumor. A left adrenalectomy was nevertheless performed and a pheochromocytoma was diagnosed.
Another patient (false negative no. 6) with false-negative HED-PET and MEN IIA also had undergone total thyroidectomy for medullary thyroid cancer but without signs of recurrence. The patient had positive biochemical tests and CT findings of bilateral adrenal gland enlargement. HED-PET was negative with low and homogenous uptake in both adrenal glands. The patient underwent bilateral adrenalectomy, and the histopathological diagnosis was a bilateral pheochromocytoma. Thus, in MEN II, the results of the HED-PET demonstrated 73% sensitivity but 100% specificity. Table 3 shows the characteristics for the 60 positive HED-PET and PET/CT examinations in 42 patients. These positive examinations included primary pheochromocytoma (n ϭ 24), secondary pheochromocytoma in the other adrenal gland (n ϭ 3), primary paraganglioma (n ϭ 2), metastatic pheochromocytoma/paraganglioma (n ϭ 30), and metastatic neuroblastoma (n ϭ 1). The impact on clinical decision making after positive HED-PET is also described in Table 3 . Table 4 shows the results of morphological imaging by CT/MRI in comparison with HED-PET and PET/CT. CT was falsely negative in a patient with small recurrent tumors in the retroperitoneal region, which were visualized by HED-PET/CT as well as by 123 I-MIBG scintigraphy, whereas somatostatin receptor scintigraphy was negative. MRI failed to visualize the tumor in two patients. In one patient, MRI failed to detect two small retroperitoneal metastases, which later were surgically removed and verified by histopathology. In the other MRI-negative case, HED-PET visualized multiple bone metastases. Table 5 shows the correlation between the PET measurements of tumor tracer uptake (SUV) in a total of 165 examinations and clinical and biochemical parameters. SUVmax correlated to positive radiological imaging, positive biochemistry, positive symptoms, and the presence of metastasis. SUVmax also correlated significantly with plasma normetanephrine, urinary norepinephrine, and the urinary norepinephrine to creatinine ratio. There was no significant correlation between SUVmax or SUVaverage and Ki-67 or between any SUV parameter and tumor size. There was no significant difference in the SUV parameters between pheochromocytomas and paragangliomas.
Patients with positive HED-PET and PET/CT
Comparison of CT/MRI and HED-PET
Correlation between PET measurements and clinical and biochemical parameters
PET measurements in malignant vs. benign tumor lesions
The PET measurements from the 60 HED-PET positive examinations were analyzed. The tumors in the remaining adrenal gland in two MEN II patients and one VHL patient, who had undergone adrenalectomy, were included in the group of primary tumors in this analysis. The SUVmax and SUVmax/SUVliver data were significantly higher in metastases than in the primary tumors (P ϭ 0.023 and P ϭ 0.018, respectively). The SUVmax, SUVaverage, and SUVmax/SUVliver in sporadic primary tumors was significantly lower than in the tumors associated with MEN II, VHL, and NF1 (P ϭ 0.033, P ϭ 0.027, and P ϭ 0.033, respectively).
PET measurements compared with normal adrenal glands
Unpaired and paired analyses were performed to compare the SUV parameters in tumors and normal adrenal glands (Table 5) . Patients who had bilateral adrenalectomy and false-negative examinations were eliminated from this comparison. Comparison toward 100 normal adrenal glands (unpaired analysis) as well as toward the contralateral normal adrenal gland in each patient (paired 
Discussion
This study confirmed previously published results from our department (20) and demonstrated that HED-PET and PET/CT are highly sensitive tools for detecting catecholamine-producing tumors including metastatic lesions in malignant disease. The aim of this paper was to evaluate the efficacy of this tracer based on 170 examinations performed at our center over 11 yr. The diagnosis of pheochromocytoma/paraganglioma relies on biochemical analysis of blood and urine and on imaging studies, usually CT or MRI, to detect the anatomical site of the tumor. In some patients conventional radiological imaging fails and functional methods may be needed, especially in malignant pheochromocytoma/paraganglioma, where metastases can be difficult to identify (Table 4 ). In many hospitals 123 I-MIBG scintigraphy remains the standard functional imaging method, but it suffers from the low spatial resolution of SPECT. PET offers better spatial resolution, and the combined PET/CT scanners available currently allow more precise anatomical correlation of the PET findings. Also, convenient attenuation correction of the PET images may be performed by the CT examination, and this has decreased the examination time considerably compared with stand-alone PET. In our study, however, CT was performed without contrast enhancement because a low-dose examination for attenuation correction for the purpose of anatomical correlation of the PET findings.
Moderate physiological HED accumulations are seen in organs with sympathetic innervation, such as the myocardium, liver, spleen, pancreas, salivary glands, and normal adrenal medulla, but these accumulations are easily recognized and in our experience have not led to falsepositive results. HED-PET and PET/CT were basically performed in two clinical situations. In patients who had previously undergone adrenalectomy or resection of paraganglioma, the examination was performed as part of a follow-up program to detect recurrent or metastatic disease, regardless of the presence or absence of sympathetic symptoms. Conversely, in most cases in the preoperative setting, HED-PET and PET/CT were considered after the patient had first demonstrated excess hormonal levels in plasma and/or urine or in patients with sympathicomi- metic symptoms. A small third group of patients underwent HED-PET and PET/CT as part of a screening procedure because of the suspect or presence of MEN II, VHL, and NF1, in which there is a high risk of developing pheochromocytoma. The overall examination-based sensitivity for HED-PET and PET/CT was high (91%), but for the subgroup of patients with hereditary syndromes, it was merely 73%. The overall specificity in all groups was 100% (Table 2 ). In the group of sporadic pheochromocytomas, the sensitivity for HED-PET and PET/CT is similar to what has been demonstrated for other PET tracers for imaging of pheochromocytoma and paraganglioma (4, 13, 14) . The lower sensitivity of HED-PET and PET/CT for the hereditary tumors is most likely due to smaller lesions, usually explored before obvious clinical symptoms were presented and presumably before higher production of catecholamine occurred. Five of the missed lesions were merely 1-1.5 cm in diameter, which is close to the spatial resolution of the PET camera. In the sixth missed tumor, 2.5 cm in diameter, the HED uptake was lower than in the contralateral normal adrenal, and this lesion was therefore overlooked. By contrast, in metastatic tumors even the smallest metastasis 1-1.5 cm in diameter was detected, again suggesting higher hormone production in metastatic tumors. This is further supported by the finding that the HED uptake (SUVmax, SUVaverage) in the tumors correlated significantly to the plasma levels of normetanephrine, and the urinary levels of norepinephrine and norepinephrine/creatinine. SUVmax showed no correlation to the Ki-67 index or to tumor size. This may imply that the degree of proliferation diagnosed by Ki-67 is not clearly related to hormonal production. A large variation was, however, seen in this respect, and some small tumor metastases had a very high SUV, whereas some large tumor lesions displayed low HED uptake.
In the comparison of HED-PET and PET/CT with morphological imaging, CT/MRI showed false-negative results for small metastatic pheochromocytoma/ganglioma lesions. There were also some false-positive findings by CT/MRI, such as in adrenal hyperplasia or adrenocortical adenoma. These results give emphasis to the need for functional imaging in patients with biochemically evident pheochromocytoma/paraganglioma and especially in malignant disease.
There are several limitations of this study as follows; there is an underrepresentation of metastatic disease; there are no patients with mutations in SDHB, succinyl dehydrogenase subunit C, or succinyl dehydrogenase subunit D included; and there is only a small number of extraadrenal paraganglioma in the series. Also, the image correlation with other, more generally available scanning techniques such as MIBG, SPECT, and other PET tracers are lacking and needs to be performed in the future evaluation of HED-PET/CT. There were merely two patients with neuroblastomas in the present study in which HED-PET was true positive for metastases in one subject but false negative in the other patient. By contrast, a previous report showed 100% sensitivity for HED-PET in neuroblastoma patients (22) . Also, 11C-HED PET needs an inhouse cyclotron to produce the tracer, which is a limiting factor for making this method more general.
To conclude, HED-PET and PET/CT demonstrated high sensitivity and maximum specificity for the detection of sporadic pheochromocytoma and paraganglioma. Sensitivity was lower in patients with the MEN II syndrome, especially in the screening situation. Tracer uptake in tumor tissue, measured as SUV, correlated with catecholamine concentrations but not with Ki-67 or tumor size. The SUV was higher in metastatic lesions than in primary tumors, possibly indicating that HED-PET/CT may be used to monitor the effects of medical therapy in patients with metastatic disease.
